IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma: Dd was approved for the treatment of relapsed/refractory CTCL patients expressing CD25, the high-affinity subunit of IL-2R, under the brand name Ontak in 1999 (13, 14).